AIMDTechnology · Scientific & Technical Instruments

AIMD Stock Forecast: Ainos, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026

$1.45

+9.02% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap

$9.8M

Ticker Nerd rank

18 / 100

Median analyst target

—

Analysts covering

Total return, dividends reinvested

+9.0%

−22.5%

YTD

−11.6%

−41.1%

From 52W high

−65.9%

From 52W low

+12.4%

$1.29

$4.25

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

AIMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ainos, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Size

Growth

Momentum

Revisions

Quality

Issuance

Volatility

Value

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (0): The shares cost a lot relative to the profits and assets behind them.

The rank is the raw material. Whether the rules would actually own Ainos, Inc. — and when they’d sell — is the membership.

Wall Street

AIMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AIMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

AIMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Ainos, Inc. (AIMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.4×
Price / sales: 581.5×
Price / book: 1.5×
EV / EBITDA: −2.5×

Growth & margins

Revenue growth (YoY): −99.8%
Earnings growth (YoY): −99.8%
Gross margin: −373.9%
Operating margin: −1418414.3%
Net margin: 82.9%

Returns & dividend

Return on equity: −148.2%
Return on assets: −33.8%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AIMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelScientific & Technical Instruments

Company	Market cap	TKN rank
AIMDAinos, Inc.	$9.8M	18
ARAIArrive AI, Inc.	$12.2M	5
ASTCAstrotech Corp.	$13.1M	23
FCUVFocus Universal, Inc.	$8.2M	12
ELSEElectro-Sensors, Inc.	$26.9M	73
MINDMIND Technology, Inc.	$45.0M	18
ACFNAcorn Energy, Inc.	$47.2M	29

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIMD appears on the weeks it earns a place.

News

Latest AIMD news & analysis

Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets

Accesswire · 3 Aug 2026positive

Ainos announced its second quarter 2026 results (period ended June 30, 2026) and provided a business update on continued execution of its AI Nose technology across semiconductor manufacturing, industrial infrastructure, robotics, and healthcare-related environments. CEO Eddy Tsai commented that AI is expanding beyond text, images, and speech toward interpreting real-world environmental information.

Why it matters — AIMD watchers would care because the update outlines the ongoing progress and market focus of the company's core AI Nose technology ahead of or alongside its quarterly financial reporting.

FAQ

Frequently asked questions about AIMD stock

How does Ticker Nerd's model rank AIMD?

As at 1 Aug 2026, Ainos, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

What is the AIMD stock forecast for 2030?

No analyst covering Ainos, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIMD are extrapolating price history, which says nothing about the business.

How has AIMD stock performed over the past year?

Ainos, Inc. returned -41.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ainos, Inc. do?

Ainos Inc. is a dual-platform AI and biotech company focused on pioneering smelltech and immune therapeutics.

What is the latest news on AIMD?

The most recent item we track (Accesswire, 3 Aug 2026): "Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets". Ainos announced its second quarter 2026 results (period ended June 30, 2026) and provided a business update on continued execution of its AI Nose technology across semiconductor manufacturing, industrial infrastructure, robotics, and healthcare-related environments. CEO Eddy Tsai commented that AI is expanding beyond text, images, and speech toward interpreting real-world environmental information.

Company

About Ainos, Inc.

Ainos Inc. is a dual-platform AI and biotech company focused on pioneering smelltech and immune therapeutics. Its smelltech platform, powered by AI Nose and a smell language model (SLM), digitizes scents into Smell ID, a machine-readable data format that enables intelligent sensing in robotics, smart factories, and healthcare applications. The company develops VELDONA®, a low-dose oral interferon therapy targeting rare, autoimmune, and infectious diseases, with active clinical programs in areas such as HIV-related oral warts, primary Sjögren’s syndrome, and feline chronic gingivostomatitis. Ainos Inc. also leverages proprietary sensor array technologies to advance healthcare AI and offers point-of-care testing devices, including antigen rapid test kits. These innovations position Ainos Inc. at the intersection of AI-driven diagnostics, scent digitization, and therapeutic solutions, serving medtech needs in diverse healthcare and technology sectors. Incorporated in 1984 and headquartered in the United States, Ainos Inc. continues to redefine machine perception through its integrated AI and biotech capabilities.

CEO Mr. Chun-Hsien Tsai · 41 employees · United States · https://www.ainos.com